Portal de Periódicos da CAPES

Prevalencia de interacciones medicamentosas con fármacos anti-retrovirales en Buenos Aires, Argentina

2016; SciELO; Volume: 33; Linguagem: Inglês

10.4067/s0716-10182016000700006

0717-6341

Ezequiel Córdova, Norma Porteiro, Eliana Loiza, Horacio Mingrone,

Pneumocystis jirovecii pneumonia detection and treatment

Prevalence of potential drug-drug interactions involving antiretroviral drugs in Buenos Aires, ArgentinaIntroduction: Antiretroviral agents (ARVs) have a high potential for drug interactions.However, the prevalence and risk factors for clinically significant drug-drug interactions (CSDDIs) with ARVs from Latin American countries is unknown.Aim: To evaluate the prevalence and risk factors for CSDDIs in HIV outpatients attending at two centers in Buenos Aires, Argentina.Methods: Descriptive cross-sectional study (september to november 2012).HIV-1 infected patients under ARV treatment at the time of the study were randomly assessed for concomitant medication.CSDDIs were screened using the University of Liverpool Drug Interactions Program (www.hiv-druginteractions.org).Results: A total of 217 patients were included.Male sex: 64% (CI 95: 57-70).Median age (IQR): 41 (36-48).Presence of comorbidities: 19%.ARV regimen: NNRTI-based: 48%, PI-based: 50% and NNRTI plus PI: 2%.Median of CD4 T-cell count (IQR): 402 cells/mL (235-588).Viral load < 50 copies/mL: 78%.Overall, 64% (CI 95: 57-70) of patients had ≥ 1 co-medication of whom a 49% had at least one CSDDI.Two patients had a CSDDI between ARVs.The most frequent co-medications observed were antimicrobial (40%), cardiovascular (25%) and gastrointestinal agents (22%).In the multivariate analysis the number of co-medications and use of CNS agents were associated with the presence of CSDDIs.Conclusions: Co-medications and CSDDIs were common in our setting.In this context, training of HIV physicians in drug interactions is of major importance for adequate management of these patients.